Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 16/20 | 0.63 |
| ▸ | PRKDC | P78527 | 15/20 | 0.63 |
| ▸ | ATR | Q13535 | 14/20 | 0.47 |
| ▸ | ATRIP | Q8WXE1 | 12/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 13/20 | 0.46 |
| ▸ | MTOR | P42345 | 5/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21541883 | 1.00 | ATM (0.63) | ATMPRKDCATRATRIPPIK3CB | |
| SCHEMBL21541879 | 0.88 | PRKDC (0.81) | ATMPRKDCATRATRIPPIK3CB | |
| SCHEMBL21541830 | 0.88 | ATM (0.58) | ATMPRKDCATRATRIPPIK3CB | |
| SCHEMBL30359521 | 0.88 | PRKDC (0.81) | ATMPRKDCATRATRIPPIK3CB | |
| SCHEMBL29559178 | 0.88 | ATM (0.58) | ATMPRKDCATRATRIPPIK3CB | |
| SCHEMBL23093848 | 0.86 | ATM (0.61) | ATMPRKDCATRATRIPPIK3CB | |
| SCHEMBL21541794 | 0.84 | ATM (0.62) | ATMPRKDCATRATRIPPIK3CB | |
| SCHEMBL30359526 | 0.84 | ATM (0.62) | ATMPRKDCATRATRIPPIK3CB | |
| SCHEMBL21541760 | 0.83 | PRKDC (0.73) | ATMPRKDCATRATRIPPIK3CB | |
| SCHEMBL21541772 | 0.80 | PRKDC (0.77) | ATMPRKDCATRATRIPPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3567041-A9 | SUBSTITUTED FUSED HETEROARYL COMPOUND SERVING AS A KINASE INHIBITOR, AND APPLICATIONS THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2022-04-20 | — | — | EP | claimed |
| CN-119215050-A | Application of substituted imidazoquinoxaline compound in preparation of anti-cancer drugs | 上海瑛派药业有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-119080781-A | Substituted imidazoquinoxaline compounds and uses thereof | 上海瑛派药业有限公司 | 2024-12-06 | — | — | CN | disclosed |
| CN-114787162-B | Substituted imidazoquinoxaline compounds and uses thereof | 上海瑛派药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-110167941-B | Substituted fused heteroaryl compounds as kinase inhibitors and uses thereof | 上海瑛派药业有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-114787162-A | Substituted imidazoquinoxaline compounds and uses thereof | 上海瑛派药业有限公司 | 2022-07-22 | — | — | CN | disclosed |
| EP-4028400-A1 | SUBSTITUTED IMIDAZOQUINOXALINE COMPOUNDS AND USES THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2022-07-20 | — | — | EP | disclosed |